Literature DB >> 30659826

Magnesium lithospermate B prevents phenotypic transformation of pulmonary arteries in rats with hypoxic pulmonary hypertension through suppression of NADPH oxidase.

Tao Li1, Xiu-Ju Luo2, E-Li Wang1, Nian-Sheng Li1, Xiao-Jie Zhang1, Feng-Lin Song3, Jin-Fu Yang3, Bin Liu4, Jun Peng5.   

Abstract

Magnesium lithospermate B (MLB) shows multiple biological activities including anti-oxidation and anti-proliferation in various diseases. However, the function of MLB in pulmonary arterial hypertension (PAH) is still unknown. This study aims to investigate the effect of MLB on hypoxia-induced phenotypic transformation of pulmonary arterial smooth muscle cells (PASMCs) and the underlying mechanisms. SD rats (or PASMCs) were exposed to 10% O2 for 3 weeks (or 3% O2 for 48 h) along with MLB or NADPH oxidase (NOX) inhibitor intervention. The effects of MLB on hemodynamics, pulmonary vascular remodeling and phenotypic transformation of PASMCs were observed first. Then, its effects on the protein levels of NOX (NOX2 and NOX4), ERK and p-ERK were examined. The results showed that MLB prevented the elevation in right ventricular systolic pressure and the increase in ratio of wall thickness to vessel external diameter of pulmonary arteries in PAH rats, and attenuated phenotypic transformation of PASMCs (decrease in α-smooth muscle actin while increase in osteopontin), accompanied by downregulation of NOX (NOX2 and NOX4) protein levels, decrease of ROS and H2O2 production, and suppression of the phosphorylation of ERK. NOX inhibitor (VAS2870) achieved similar results to that of MLB did in the hypoxia-treated PASMCs. Based on the observations, we conclude that MLB is able to prevent phenotypic transformation of pulmonary arteries in hypoxic PAH rats through suppression of NOX/ROS/ERK pathway, and MLB might have the potentials in PAH therapy.
Copyright © 2019 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Magnesium lithospermate B; NADPH oxidase; Phenotypic transformation; Pulmonary arterial hypertension; Pulmonary vascular remodeling

Mesh:

Substances:

Year:  2019        PMID: 30659826     DOI: 10.1016/j.ejphar.2019.01.020

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  8 in total

1.  Association Between Inflammatory Mediators and Pulmonary Blood Flow in a Rabbit Model of Acute Pulmonary Embolism Combined With Shock.

Authors:  Yuting Wang; Delong Yu; Yijun Yu; Xiaoyan Liu; Liqun Hu; Ye Gu
Journal:  Front Physiol       Date:  2020-09-02       Impact factor: 4.566

2.  NOX Inhibitors: From Bench to Naxibs to Bedside.

Authors:  Mahmoud H Elbatreek; Hermann Mucke; Harald H H W Schmidt
Journal:  Handb Exp Pharmacol       Date:  2021

3.  Comprehensive Analyses of miRNA-mRNA Network and Potential Drugs in Idiopathic Pulmonary Arterial Hypertension.

Authors:  Chan Li; Zeyu Zhang; Qian Xu; Ruizheng Shi
Journal:  Biomed Res Int       Date:  2020-07-03       Impact factor: 3.411

Review 4.  Pathophysiology and Therapeutic Potential of NADPH Oxidases in Ischemic Stroke-Induced Oxidative Stress.

Authors:  Jinnan Duan; Shiqi Gao; Sheng Tu; Cameron Lenahan; Anwen Shao; Jifang Sheng
Journal:  Oxid Med Cell Longev       Date:  2021-03-09       Impact factor: 6.543

Review 5.  Traditional Herbal Medicine Discovery for the Treatment and Prevention of Pulmonary Arterial Hypertension.

Authors:  Zhifeng Xue; Yixuan Li; Mengen Zhou; Zhidong Liu; Guanwei Fan; Xiaoying Wang; Yan Zhu; Jian Yang
Journal:  Front Pharmacol       Date:  2021-11-09       Impact factor: 5.810

6.  Evaluating the therapeutic role of selected active compounds in Plumula Nelumbinis on pulmonary hypertension via network pharmacology and experimental analysis.

Authors:  Xinghua Xiao; Fangmei Luo; Minyi Fu; Yueping Jiang; Shao Liu; Bin Liu
Journal:  Front Pharmacol       Date:  2022-08-17       Impact factor: 5.988

Review 7.  Medicinal Plants and Phytochemicals for the Treatment of Pulmonary Hypertension.

Authors:  Seyed Vahid Jasemi; Hosna Khazaei; Ina Yosifova Aneva; Mohammad Hosein Farzaei; Javier Echeverría
Journal:  Front Pharmacol       Date:  2020-03-12       Impact factor: 5.810

Review 8.  Nutraceuticals in the Treatment of Pulmonary Arterial Hypertension.

Authors:  José L Sánchez-Gloria; Horacio Osorio-Alonso; Abraham S Arellano-Buendía; Roxana Carbó; Adrián Hernández-Díazcouder; Carlos A Guzmán-Martín; Ivan Rubio-Gayosso; Fausto Sánchez-Muñoz
Journal:  Int J Mol Sci       Date:  2020-07-08       Impact factor: 5.923

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.